STOCK TITAN
  1. Home
  2. News
  3. CHEK

Check-Cap Ltd - CHEK STOCK NEWS

Welcome to our dedicated news page for Check-Cap (Ticker: CHEK), a resource for investors and traders seeking the latest updates and insights on Check-Cap.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Check-Cap's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Check-Cap's position in the market.

News
Nobul AI Corp and Check-Cap Ltd Enter into Definitive Business Combination Agreement
Rhea-AI Summary
Nobul AI Corp. and Check-Cap have agreed to a business combination to form a North American technology company focusing on an AI-driven fintech marketplace. The combined company, if approved, will be listed on NASDAQ and TSX, with Nobul's executive team leading the merged entity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.7%
Tags
AI
-
News
SYMETRYX COMMENTS ON SUCCESSFUL CAMPAIGN AT CHECK-CAP LTD
Rhea-AI Summary
Symetryx Corporation (Symetryx) (NASDAQ: CHEK) successfully elected all director nominees proposed by Symetryx at the Annual General Meeting, with CHEK shareholders voting overwhelmingly against the proposed merger with Keystone Dental. President Barry R. Shiff expressed gratitude for the support and emphasized the potential upside at CHEK. Check-Cap, based in Isfiya, Israel, developed the breakthrough C-Scan technology to prevent colorectal cancer, receiving regulatory clearances in Europe and FDA Breakthrough Device Designation in 2021.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.7%
Tags
none
-
News
CHECK- CAP BOARD MEMBER';S STATEMENT ON THE STAND SUGGESTS A POTENTIAL CONFLICT OF INTEREST WITH KEYSTONE DENTAL
Rhea-AI Summary
Symetryx (NASDAQ: CHEK) recommends voting against the Keystone Dental merger and for their qualified independent board nominees. The vote deadline is 11:59 pm EST on December 14th, 2023. Symetryx continues to urge Check-Cap Ltd. shareholders to vote against the Keystone Dental and for the Symetryx slate of highly qualified and independent director nominees. A potential conflict of interest between Uri Geiger, the Chairman of Keystone Dental, and Yuval Yanai, a Check-Cap director, has been revealed during a court hearing in the Haifa Israel Economic District Court.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
News
CITING THE MANY FDA ADVERSE EFFECTS TO KEYSTONE DENTAL - CHECK-CAP FOUNDER STRONGLY RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER ALSO RECOMMENDS VOTING FOR THE SYMETRYX BOARD NOMINEES
Rhea-AI Summary
Symetryx Corporation (NASDAQ: CHEK) continues to urge Check-Cap Ltd. shareholders to vote against the Keystone Dental and for the Symetryx slate of director nominees. Keystone Dental received a deficiency letter from the FDA regarding its Paltop Short Implants, potentially harming its business and negatively impacting shareholders' investment. Hundreds of adverse events have been reported by Keystone Dental to the FDA, which may drive clinicians to choose other brands. Symetryx is urging shareholders to reject the Keystone transaction and support the Symetryx Board nominees to realize the full value of their investment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
acquisition
-
News
CHECK-CAP FOUNDER STRONGLY RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER AND FOR THE SYMETRYX BOARD OF DIRECTORS NOMINEES
Rhea-AI Summary
Symetryx Corporation (SYMX) continues to urge Check-Cap Ltd. (CHEK) shareholders to vote against the Keystone Dental transaction and for the Symetryx slate of director nominees. The company believes that the transaction with Keystone Dental does not provide the maximum value for shareholders and that only with a new, independent Board, shareholders will have the best opportunity to realize the full value of their investment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.77%
Tags
management acquisition
-
News
Symetryx Today Issues Open Letter to Shareholders In Regard to the Upcoming Annual General Meeting
Rhea-AI Summary
Symetryx Corporation (Symetryx) has issued an open letter to shareholders, urging them to vote against the proposed transaction with Keystone Dental and to support Symetryx's five director nominees. Symetryx raises concerns about the unrealistic valuation of Keystone Dental and the troubling cash burn by Check-Cap Board & Management. Symetryx fears that the proposed merger would cause an alarmingly high level of dilution to the shareholders. The Proxy Statement for the Check-Cap Annual General Meeting is scheduled for December 18th, 2023, and Symetryx recommends shareholders to vote against the Keystone Merger Proposal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
none
News
Check-Cap Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Rhea-AI Summary
Check-Cap Ltd. (NASDAQ: CHEK) shareholders will vote on a proposed Business Combination Agreement with Keystone Dental at the Annual General Meeting on Monday, December 18th. Keystone Dental will become the majority holders of the combined company, creating a public company focused on advancing commercial execution and market development of dental implant technologies. The company will trade on the NASDAQ under the symbol 'KSD'. Financial results for the third quarter and nine months ended September 30, 2023, show a decrease in research and development activities, an increase in general and administrative expenses, and a net loss of $2.6 million for the third quarter and $13.9 million for the nine months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.76%
Tags
earnings
-
News
SYMETRYX OPPOSES CHEK CAP/KEYSTONE MERGER, WILL EVALUATE OPTIONS TO STOP TRANSACTION
Rhea-AI Summary
Symetryx opposes Check-Cap/Keystone merger
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
acquisition
-
News
Check-Cap Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News
SYMETRYX CORP INCREASES NON-BINDING OFFER TO ACQUIRE CHECK-CAP TO $4.60 PER SHARE
Rhea-AI Summary
Symetryx Corporation has increased its non-binding proposal to acquire Check-Cap LTD to $4.60 per share in cash. Symetryx urges the Check Board to engage in communications and allow due diligence. The proposal is contingent upon various conditions and may create substantial value for Check shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.22%
Tags
acquisition
Stock CHEK logo
Check-Cap Ltd

Nasdaq:CHEK

CHEK Rankings

#5296 Ranked by Market Cap
#3764 Ranked by Stock Gains
N/A Ranked by Dividends

CHEK Stock Data

13.22M
4.42M
25.16%
1.08%
10.26%
Irradiation Apparatus Manufacturing
Manufacturing
Link
Israel
P O Box 1271

About CHEK

check-cap is a clinical stage medical diagnostics company leading the development of the first ingestible imaging capsule that utilizes low-dose x-rays for crc screening. the check-cap device requires no bowel preparation or invasive procedures, and is designed to detect clinically significant polyps with a high degree of sensitivity. check-cap's advanced technology has been proven in animals, and is designed to offer several advantages compared to current screening procedures. founded in early 2005, check-cap recruited a team of world-class experts in physics, software engineering, electronics, mechanics and physiology, who have been developing a multi-disciplinary imaging solution for imaging and screening of the colon. the system includes a capsule, a receiver, proprietary imaging software and an associated database for web based access and analysis. check-cap's advanced technology has been proven in animals and promises to offer several significant advantages compared to other colo